MAIA Biotechnology Inc. (MAIA) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $1.36 (-2.86%), Market cap $0.08B, 52-week low–high $0.87 ~ $2.95.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Financial statements, price targets, institutional (13F) holdings and related news for MAIA Biotechnology Inc. are updated in real time on BlackAll Trade.
MAIA Biotechnology Inc. trades at $1.36 (-2.86%). Real-time quotes and charts are available on BlackAll Trade.
MAIA Biotechnology Inc. has a market cap of about $0.08B.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a